VivaVision to advance non-steroidal therapy in Phase III following Phase II win
The company’s non-steroidal immunomodulator met the primary endpoint in a Phase II trial as a treatment for post-op inflammation following cataract surgery.
The company’s non-steroidal immunomodulator met the primary endpoint in a Phase II trial as a treatment for post-op inflammation following cataract surgery.
GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Lead Gilead researcher highlights need for inclusive clinical trials for HIV
Dr Oz nominated to lead CMS despite big pharma ties
Yonalink launches ICTN to position Israel as leader in clinical trial innovation
FDA shares additional draft guidance on CGTs